

1 **Monitoring the battleground: Antimicrobial resistance, antibiofilm patterns, and virulence**
2 **factors of wound bacterial isolates from patients in hospital system.**

3

4 Silas O. Awuor ^{a,*}, Richard Mariita ^b, Eric O. Omwenga ^c, Jonathan Musila ^d,
5 *Stanslaus Musyoki* ^e

6 *a. Microbiology Department, Jaramogi Oginga Odinga Teaching and Referral Hospital, P.O*
7 *Box 849, Kisumu, Kenya.*

8 *b. Microbial BioSolutions, Troy, New York, 12180 USA*

9 *c. Department of Medical Microbiology & Parasitology, School of Health Sciences, Kisii*
10 *University P.O. Box 408 – 40200 Kisii*

11 *d. Fayetteville State University, NC 28301 USA*

12 *e. Department of Medical Laboratory Sciences, School of Health Sciences, South Eastern Kenya*
13 *University; P.O. Box 170-90200, Kitui, Kenya*

14

15 * Corresponding author: awuorhsd@otti.ac.ke

16

17 Email address

18 1. RM- richard.mariita@microbialbiosolutions.com

19 2. EO- omorieric@kisiiversity.ac.ke

20 3. JM- jmusila@broncos.uncfsu.edu

21 4. SM- stanslausmusyoki01@gmail.com

22

23

24

25 **ABSTRACT**

26 Extensive use of antibiotics in the treatment of bacterial infections has led to a challenge of antibiotic
27 resistance, contributing to morbidity and mortality. Herein, evaluation of bacterial isolates from patients
28 with wound discharge was performed and drug susceptibility patterns examined, with a goal of deciphering
29 antibacterial resistance. A cross-sectional study was conducted between March to June 2022, in which
30 samples were collected from patients with chronic wounds and were inoculated into appropriate media for
31 identification and characterization. The bacterial pathogens were identified using standard microbiological
32 methods. Shockingly, the majority of wound isolates showed positive growth in microbial analysis
33 with high prevalence in male candidates. Further, *Staphylococcus aureus* 28 (20.7%) was
34 identified as the most predominant pathogen followed by *Klebsiella spp.* 20 (14.8%), *P.*
35 *aeruginosa spp.* 10 (14.8%) and lastly *E. coli* 6 (4.4%) bacteria in the wound isolates while
36 cotrimoxazole 13 (48.1%) followed by clindamycin 7 (25.9%) and erythromycin 7 (25.9%) were
37 the most antibacterial resistant drugs to both Gram positive and Gram-negative bacteria. Out of
38 the four isolates, 3 (75%) isolates were able to produce the haemolysin and protease and 2 (50%)
39 isolates were able to produce the lipase and phospholipase. The findings herein form a clinical
40 basis for identification of antimicrobial resistance in chronic wounds that can be applied in
41 responsible use of antibacterial in chronic wound management and as an illumination in
42 development of more potent antibiotics for chronic wound treatment

43

44

45

46 **Keywords:** Antibiofilm, antimicrobial resistance, human pathogens, susceptibility, virulence,

47

48

49

50 Introduction

51 The six pathogens represented in the acronym ESKAPE (*Enterococcus faecium*, *Staphylococcus*
52 *aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and
53 *Enterobacter* species) exhibit multidrug-resistance and virulence, and are attributed to a majority
54 of nosocomial infections [1,2]. These organisms mostly infect wounds as it offers a moist, warm,
55 nutritive environment advantageous to microbial colonization, spread, and infection [3–6].
56 Different bacterial species live on human skin, in the nasopharynx, gastrointestinal tract, and other
57 parts of the body with little latent for causing disease, because of the skin being the first line of
58 defense within the body [7, 8]. Any breach in the skin surface whether through contact with
59 contaminated water, trauma, accident, surgical operation, or burn provides an open door for
60 bacterial infections [7]. Consequently, wounds can be infected by a diverse array of
61 microorganisms ranging from bacteria to fungi and parasites as well as viruses [9,10].

62 Unfortunately, the control of wound infections has become more challenging due to widespread
63 bacterial resistance to antibiotics, and to a greater incidence of infections caused by methicillin-
64 resistance *S. aureus*, polymicrobial flora [11]. Although modernization of antimicrobials in the
65 20th and 21st century was meant to transform treatment of human infections; the fast-increasing
66 antimicrobial resistance poses a threat to mitigating infections. Antimicrobial resistance remains a
67 dynamic risk to the management of the rising range of infections caused by microorganisms [12],
68 hence antibacterial drugs effectiveness is reduced making the management of patients demanding
69 and expensive inducing persistent sickness and increasing deaths on helpless patients [12].
70 Progress of antimicrobial resistance is a normal incidence in microorganisms which is boosted due
71 to burden brought about by usage and mistreatment of antibiotics in organisms [13]. Lately, there
72 has been a developing desire for identification antibiotics which are more powerful in resistant
73 bacteria management [13]. This is because the chief common bacteria have developed resistance
74 to common antimicrobials discovered recently [13, 14]. The absence of fresh antibiotics in the
75 World to substitute the incompetent one conveys more urgency to the desire to guard the
76 effectiveness of current medications, advancement and
77 enactment of suitable methods to curb the rise and spread of antimicrobial resistance [15].

78 In developing countries, antimicrobial resistance poses a great trial to community health care
79 motivating several researchers to determine the resistance profile of antibiotics against bacteria.
80 Nevertheless, the conclusions continue to produce different opinions on the drug's effectiveness.

81 For instance [16, 17] in Libya like [18] in Sudan revealed sensitivity to 54% amikacin and 59%
82 ciprofloxacin but resistance to 81% vancomycin, 75% amoxicillin, 92% streptomycin, 45%
83 tetracycline, 26% methicillin, 65% amoxicillin, and 46% erythromycin. On the other hand, it was
84 displayed that bacteria were highly resistant to 96% ciprofloxacin in Nigeria [19], which opposes
85 other findings.

86 The increasing problem of antimicrobial resistance remains a worrying nightmare across the world
87 prompting endless research and innovation approaches research on bacterial susceptibility and
88 resistance to antibiotics is a top interest sometimes presenting contradicting findings. For example,
89 in wound management, [19, 20] recognized that bacterial isolates were therapeutically responsive
90 to amoxicillin clavulanate, meropenem, clindamycin, ceftriaxone, piperacillin-tazobactam,
91 ciprofloxacin, vancomycin, levofloxacin, linezolid, teicoplanin, imipenem, meropenem, amikacin
92 and levofloxacin but resistant to ampicillin, Amoxicillin clavulanate, cotrimoxazole, doxycycline
93 and cephalosporins. Later studies [20] with similar focus presented e highly resistance to
94 cephalosporins, amoxicillin clavulanate and imipenem with disregard to [21] findings.

95

96 **Materials and Methods**

97 An examining study was carried out in all the samples receive at the Medical Microbiology
98 Laboratory Department of Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH),
99 Kisumu county-Kenya for the period of March to June 2022. Samples (wound pus/swab) were
100 obtained from the patients who only attend JOOTRH both in Outpatient and Inpatient
101 department, patient referend to the hospital were not included in this study.

102 Following aseptic techniques, microscopy was performed to analyze for type and morphology of
103 bacteria. The samples were then inoculated on blood agar (BA), Mac-conkey agar (MA) and
104 chocolate agar (CA) following previously used and established standard protocols [22]. BA and
105 MA plates were incubated aerobically, while CA plates were incubated in anaerobic condition at
106 37°C for 24 to 48 hours in the incubator. All the isolates were identified by colony morphology,
107 Gram staining reaction and the biochemical properties [22]. The antimicrobial susceptibility test
108 of isolates was performed by the Kirby-Bauer disc diffusion method using the CLSI guidelines
109 on Müeller-Hinton agar plates (Mast Diagnostics Ltd, Merseyside, UK) where 16 antimicrobials
110 i.e. penicillin (25 µg), Ampicilin (10 µg), Vancomycin (15 µg), Cefoxitin (10 µg), Cefuroxime
111 (30 µg), Oxacillin (15 µg), Ciprofloxacin (10 µg), Clindamycin (25 µg), Co-trimoxazole (30

112 µg), Tetracycline (15 µg), Erythromycin (10 µg), Gentamicin (30 µg), Ceftriaxone (10 µg),
113 cefepime (30 µg), Imipenem (10 µg) and Amikacin (30 µg) will be used in this study as
114 outlined by Clinical and Laboratory Standards Institute (CLSI) (2022) [23]. After this isolated *S.*
115 *aureus* was screened for methicillin resistance using cefoxitin disc (30 µg) as per standard
116 guidelines provided by CLSI, (2022). MICs of ciprofloxacin and gentamicin were determined by
117 agar dilution method [25, 26] and the guidelines of the CLSI [23]. The tests were performed by
118 making a series of antibiotic concentrations on Mueller–Hinton agar (MHA) plates. *P.*
119 *aeruginosa* spp. ATCC® 12934 and *S. aureus* ATCC® 29213 were used as reference strains
120 (controls). All the data were entered in SPSS version 20 and GraphPad Prism version 9.4.
121 Statistical analyses were done using the same software.

122 **Biofilm formation inhibition assay**

123 As described by Awuor et al. [27], microtiter plate assay was performed to quantify the effect of
124 commonly used antibiotics on the biofilm formation of *P. aeruginosa* spp. strains. The test
125 bacteria were first inoculated on Luria-Bertani (LB) medium agar and incubated at 37 °C
126 overnight. Then a colony was identified, picked and inoculated in 10 ml of LB broth and
127 incubated at 37 °C overnight while shaking at 100 r.p.m. for 18 h. By use of a parafilm the flat-
128 bottomed polystyrene tissue culture microplate was sealed for purposes of preventing medium
129 evaporation. After 48 h incubation, the wells were carefully rinsed with double-distilled water to
130 remove loosely attached cells. The microplate was air-dried for 1 h before adding 200 µL per
131 well of 0.4 % crystal violet (CV) solution to the adhered cells in the wells and then stood at room
132 temperature for 15 min. Excess stain was removed by rinsing the wells gently with 200 µL per
133 using distilled water. This was repeated thrice. The microtiter plate was then air-dried for 1 h
134 after, followed by addition of 200 µL of absolute ethanol to each well to solubilize the dye. The
135 OD was measured at OD_{590nm} using a Safire Tecan-F129013 Microplate Reader (Tecan,
136 Crailsheim, Germany). For each experiment, background staining was corrected by subtracting
137 the crystal violet bound to un-treated controls (Blank) from those of the tested sample. The
138 experiments were done in triplicate and average OD_{590nm} values were calculated. To estimate the
139 antibiofilm activity (Abf A) of a given antibiotic the following equation was used,

$$140 \text{ Abf A (\%)} = (1 - (\text{OD}_{\text{Test sample}} - \text{OD}_{\text{Blank}}) / (\text{OD}_{\text{Untreated sample}} - \text{OD}_{\text{Blank}})) \times 100.$$

141 **Monitoring presence of relevant virulence factors of *P. aeruginosa* spp.**

142 **(i) Detection of haemolysin**

143 Haemolysin production by the *P. aeruginosa* spp. isolates were detected following protocols by
144 Benson et al. [28]. The β -haemolytic activity was tested for on base agar (Himedia, India)
145 supplemented with 7 % sheep erythrocytes for 18–24 h. Pure isolates were cultured on TSA,
146 before streaking on blood agar and further incubated for 24 h at 37 °C. Zones of haemolysis
147 around the colonies indicated the ability of these bacteria to haemolyse RBCs [40].

148 **(ii) Detection of protease**

149 To detect protease production by the *P. aeruginosa* spp. isolate skim milk agar was used and the
150 protocol that was described in [28]. Briefly, two solutions (A and B) were made and used in this
151 study. Solution A was prepared by adding 10 g skim milk to 90 ml of distilled water then volume
152 was completed to 100 ml gently heated at 50 °C, then autoclaved and cooled to 50–55 °C. And
153 solution B was also prepared by adding 2 g of agar powder to 100 mL of distilled water, mixed
154 thoroughly, then autoclaved and cooled to 50–55 °C. Aseptically, 100 ml of solution A was
155 mixed with 100 mL of solution B. Then the mixture was poured into sterile petri dishes, and then
156 stored at 4 °C until use. This media used to detect the ability of the bacteria to produce protease
157 [46]. The appearance of a cleared hydrolysis zone indicates a positive test [29].

158 **(iii) Detection of lipase**

159 Lipase production ability by *P. aeruginosa* spp. isolates were determined by methods outlined by
160 Elliot et al. [29]. Briefly, a single colony of an overnight growth was cultured on Rhan medium,
161 and then incubated for 1–5 days at 37 °C. The appearance of a turbid zone around colonies
162 indicates a positive result [28].

163 **(iv) Detection of lecithinase (phospholipase)**

164 To detect lecithinase, we followed a standard procedure [30]. One pure colony was cultured on a
165 medium of phospholipase activity assay followed by incubation for 1–3 days at 37 °C using
166 established procedures [31]. The appearance of a white to brown colour elongated precipitated
167 zone around colonies is considered a positive result [32].

168 **Validity and reliability**

169 All experiments were conducted in triplicates that were independent of each other to validate
170 reproducibility.

171 **Data analysis**

172 Statistical analysis was performed using Graph pad Data on socio-demographics were summarized
173 by frequencies and percentages. All values of diameter zones of inhibition are reported as mean \pm
174 standard error.

175 **Ethical consideration**

176 Confidentiality and privacy were strictly adhered to and no names of individuals were recorded or
177 made known in the reporting of information. The study was granted ethical clearance by the
178 Institutional Research Ethics Committee (IREC) at Jaramogi Oginga Odinga Teaching and
179 Referral Hospital (JOOTRH), written informed consent was obtained from the parent/guardian of
180 each participate in this study.

181

182 **Results.**

183 Of 135 samples processed, 73 (54.1%) showed their growth as shown in **Supplementary data 1.**
184 **A-F.** Among growth positive cases, 37(27.4%) were Gram positive while 36 (26.7%) were Gram
185 negative and 62 (45.9%) did not show growths. High rate of growth positive rate in infection was
186 found in case of male gender with Gram-positive cocci isolates at 23 (29.1%) and Gram-negative
187 cocci isolates at 26 (32.9%) than female gender with Gram-positive isolates of 14 (25.5%) and
188 Gram-negative isolates of 10 (18.2%), which were found to be statistically significant (p-value <
189 0.075). Among total growth, the highest growth rate was found in age groups >45 years in both
190 Gram-positive and Gram-negative at 14 (26.9%) and 12 (23.1%) respectively. Least growth was
191 found in an age group of < 5 years and 25-34 years as shown in **Table 1.**

192 Out of the total wound swab samples analyzed 71 (52.6%) were from swab while 64 (47.4%)
193 were aspirate samples in which higher percentage growth was observed on aspirate than swab
194 sample as in **Table 2.** Out of the 73(54.1%) growth positive wound swab samples,37 (27.4%)
195 Gram- positive bacteria were found, while 36 (26.7%) Gram- negative bacteria were isolated.
196 Among the Gram-positive isolates, *S. aureus* 28 (20.7%) was the most predominant followed by
197 *Staphylococcus spp.* 9 (6.7%) while in Gram-negative isolates the most predominant organism
198 was *Klebsiella spp.* 20 (14.8%) followed by *P. aeruginosa spp.* 10 (14.8%) and lastly *E. coli* at 6
199 (4.4%) as shown in **Table 2.**

200 Among 37 (27.4%) Gram-positive isolates, 28 (20.7%) *S. aureus* resistance pattern showed that
201 the most effective antibiotics were cotrimoxazole 13 (48.1%) followed by clindamycin 7 (25.9%)
202 and erythromycin 7 (25.9%) while lower resistant to cotrimoxazole 3 (37.5%) was observed on
203 *Staphylococcus spp.* as compared to *S. aureus*. In 36 (26.7%) Gram-negative isolates, 20 (14.8%)
204 *Klebsiella spp.* resistance pattern showed that the most affected antibiotic was tetracycline 11
205 (61.1%) followed by gentamicin at 9(50%) while for *P. aeruginosa* four isolates show MRD to
206 commonly used antibiotics, while for *E. coli* it was found that the isolates were sensitive to
207 almost all of the common antibiotic used in the facility for their management as shown in **Table**
208 **3** and **Supplementary data 2. A-C**.

209 Among the total 10 (7.4%) *P. aeruginosa* isolates, 4 isolates (**12583;14421;1364 & 11985**) were
210 found to have multi drug resistance. Among MDR isolates, 2 isolates (**12583 & 13642**) were
211 resistant to 3 antimicrobial classes, 1 isolate (**13642**) was resistant to four antimicrobial classes; 2
212 isolates (**14421 & 13642**) were resistant to five classes; 1 isolate (**11985**) was resistant to six
213 antimicrobial Classes as shown in **Fig. 1**.

214 This study investigated the production of various virulence enzymes like protease,
215 phospholipase, lipase and haemolysin on the four *P. aeruginosa* isolates which showed MRD
216 and were found to be resistant to common antibiotics used for its management within the study
217 area. It was revealed that out of the 10 isolates four isolates showed resistance at different
218 antimicrobial classes in which out of the four isolates, isolate **14421** was able to produce all
219 types of the virulence enzymes. Also, it was confirmed that isolate **12583** was able to produce all
220 enzymes except phospholipase enzyme while isolate **11985** was also capable of producing all
221 except lipase enzyme. Lastly, it was determined that isolate **13642** was not able to produce all the
222 virulence enzymes as shown in **Table 4**.

223 The isolates showed that the biofilm formation inhibitory effects of the various concentrations
224 (0.5, 0.25, 0.125, 0.0625 and 0.03125 mg ml⁻¹) were significantly lower than that of the
225 positive control, an indication that biofilm formation was inhibited at these concentrations (**Figs.**
226 **2–4**). As much as such inhibitory effects were recorded, these findings clearly demonstrate that
227 out of the four isolates that proved to be resistant to commonly used antibiotics, three isolates
228 (12583; Fig.2,14421; Fig. 3 and 11985; Fig. 4) have the ability of forming biofilms.

229 Antibiofilm formation activity against isolate 14421 of *P. aeruginosa* against various antibiotics
230 like Ciprofloxine, Cefuroxime, Ceftriaxone, Ampicillin, Gentamicin and Amikacin against
231 was observed in all the antibiotics (Fig. 4). Against ampicillin, a concentration of 0.0125 mg
232 ml^{-1} and 0.0625 yielded significant biofilm formation inhibition ($P=0.05$), while for
233 Gentamicin obtained significant differences on the biofilm formation inhibition at a
234 concentration of 0.5 mg ml^{-1} ($P=0.0001$), 0.25 mg ml^{-1} ($P=0.0001$), 0.125 mg ml^{-1}
235 ($P=0.0001$). 0.0625 mg ml^{-1} ($P=0.0001$) and 0.03125 mg ml^{-1} ($P=0.0001$) was observed in
236 all the isolates. It is more worrying that Ciprofloxine, which is the commonly used antibiotic in
237 the hospital, had less inhibitory effects against biofilm formation most so in the isolate 12583.

238 **Discussion.**

239 In this study, out of 135 samples from patients with wound infection, 73 (54.1%) samples
240 showed positive growth. In similar studies conducted earlier by [22] in antibiotic susceptibility
241 pattern of bacterial isolates causing wound infection among the patients visiting B & B Hospital
242 in India, [25] showed growth positive was 44.9% & 50% respectively. A study conducted by
243 [26,27] in the tertiary hospital in South Africa, more than 90% showed growth. Culture negative
244 results observed in this study could be attributed to the non-infective bacteria, manual error in
245 collection, transportation, overstay of samples to reach Laboratory department culture media
246 and collection of samples from patients taking antibiotics. The growth was seen to be higher in
247 male patients in both Gram- positive and Gram- negative isolates at 23(29.1%) and 26(32.9%)
248 respectively. A Similar study carried out by [24] agrees with our findings. The relatively higher
249 percentage of male patients might be due to active involvement of males in outdoor activities,
250 including agricultural work resulting in high infection possibility and prevalence of high rate of
251 accidental cases among them [28].

252 From the total growth of 54.1%, the highest growth rate was found in age group >45 years
253 followed by 6-14, 15-24, 25-34, 35-44 and lastly <5 years, our findings disagree with the studies
254 carried out by [27,28] which showed highest growth rate in age group 21-30 (25.4%), followed

255 by 31-40 (16.2%) and 11-20 (16.2%). Least growth was found in an age group of 0-10 and above
256 60 years. The reason behind this age group (>45) showing high growth among all age classes
257 may be due to high prevalence of this age group in our study as well as the group being lively
258 age group or working age group hence the chances of occurring accidents leading to hospital
259 admission.

260 From the total bacterial isolates, 37(27.6%) were Gram positive and 36 (26.9%) were Gram
261 negative bacteria. This result didn't concur with a study conducted by [21-33] which shows
262 Gram negative bacteria being predominant since their peptidoglycan layer is much thinner than
263 that of Gram-positive bacilli and they are harder to kill because of their harder cell wall in which
264 when their cell wall is disturbed release endotoxins that can make your symptoms worse [25].
265 Our observation of Gram negative as the most common bacteria in wound infections differs from
266 other studies in Nigeria reporting Gram positive to be predominant [29]. Among the gram-
267 negative isolated pathogens *Klebsiella spp.* was the most predominant 20(14.8%), The
268 pathogenicity of *K. pneumoniae* is mediated by several virulence factors that allow it to evade
269 host innate immune responses. These factors include the capsule, lipopolysaccharide, adhesins,
270 iron acquisition systems, resistance to serum, and biofilm formation [24]. While for the Gram-
271 positive *S. aureus* was the predominant isolate 28 (20.7%) and 1st predominant isolates among
272 the total. *S. aureus* pathogenicity is mediated by bacterial components and secreted virulence
273 factors such as surface-associated adhesins, capsular polysaccharide (CP), and exotoxins [29].
274 This finding didn't concur in a similar study conducted by [32], *P. aeruginosa* was the most
275 predominant one (29.9%) among the total isolates this may be due to the permeability barrier
276 afforded by its Gram-negative outer membrane, while *S. aureus* was predominant (27.5%)
277 among Gram positive isolates. The study conducted by [32] Gram-negative bacilli constituted
278 66% of all the pathogens with *P. aeruginosa* as the most frequent (19%). Higher prevalence of *S.*
279 *aureus* among Gram-positive bacteria and 1st predominant isolates among the total seen in this
280 study was also reported by other researchers, [35, 36]. Many researchers said that it is most
281 commonly isolated. *S. aureus* was ubiquitous and the most common cause of localized
282 suppurative lesions in human beings.

283 In the susceptibility patterns towards Gram-positive isolates, *S. aureus* isolates showed an
284 alarmingly resistance to cotrimoxazole (48.1%), a commonly used antimicrobial drug in wound

285 management Studies have shown *S. aureus* can become drug-resistant either via genetic
286 mutations on DNA gyrase or through reduced expression of outer membrane proteins reducing
287 drug accumulation [53]. Our findings corroborate previous studies [37] [38,39] that reported
288 47% and 49% resistance towards cotrimoxazole respectively. With cotrimoxazole has been the
289 first-line treatment for wound infections, and it is commonly prescribed not only for wound
290 infection but also for gastrointestinal tract infections, including diarrhea, but also for the
291 treatment of respiratory tract infections, urinary tract infections and skin infections. Its mode of
292 action is by targeting a subunit of DNA gyrase, which is essential in the production of bacteria
293 DNA (39). It is often prescribed to immunocompromised patients, including human
294 immunodeficiency virus (HIV) patients, which are common in the study area with a prevalence
295 of 16.3% [38]. Such a vast usage of cotrimoxazole, and the fact that it is relatively cheap and
296 could be acquired over the counter even without a prescription, may have contributed to the
297 emergence of resistance towards this antibiotic as observed in this study.

298 A high incidence of Erythromycin resistant to *S. aureus* isolates (25.9%) was also observed.
299 Erythromycin is a bacteriostatic and broad-spectrum antibiotic effective against a wide variety of
300 Gram-positive bacteria. Its mode of action is by irreversibly binding to a receptor site on the 50S
301 subunit of bacterial ribosome, inhibiting peptidyl transferase, consequently resulting in the
302 prevention of amino acid transfer to growing peptide chains, leading to inhibition of protein
303 synthesis. Up to late 2018, it was used as the first-line antibiotic treatment for typhoid and other
304 *Salmonella* infections [32]. However, because of resistance and safety issues, it is no longer the
305 first-line treatment in enteritis. In low-income countries, it is still widely used, as it is not
306 expensive and readily available [40]. Erythromycin has been recommended by the World Health
307 Organization (WHO) for the treatment of wound infection in both children and pregnant women
308 [44]. The high resistance observed may be explained by its frequent usage for the treatment of
309 severe cough and other infectious diseases. Also, Erythromycin resistance was found to be due
310 predominantly to the presence of an Erm(B) methylase. Other reports have indicated that *S.*
311 *aureus* isolates are resistant to Erythromycin [37]. A similar incidence was observed for other
312 pathogens causing diarrhea in a study conducted in the study area [42].

313 A higher resistance rate of *Klebsiella spp.* to ampicillin (61.1%) was observed compared to that
314 towards Gentamicin (50%), whose mode of activity is by targeting penicillin-binding proteins – a

315 group of enzymes found anchored in the cell membrane, involved in the cross-linking of
316 bacterial cell wall. *Klebsiella spp.* isolates from previous wound infections were known to
317 exhibit resistance to ampicillin, [43] Gentamicin and Imipenem [43]. There was an emergence of
318 *P. aeruginosa* isolates resistant to ampicillin (33.3%), Gentamicin, Amikacin and Ceftriaxone all
319 at (20%), with 10 isolates resistant to this antimicrobial which has been primarily associated with
320 the presence of IncC conjugative plasmids [44], hence leading to 4 isolates being found to be
321 multi drug resistance. Among the MDR isolates, 2 showed resistance to 3 antimicrobial classes,
322 1 resistant to four antimicrobial classes; 2 resistant to five classes and finally 1 was resistant to
323 six antimicrobial Classes. Studies on MRSA have shown their wide variation. Naik and
324 Deshpande (2011) [45] showed 8.0% of MRSA which agree with our study. All *E. coli* isolates
325 were sensitive towards all the antibiotics used except lower resistance to Imipenem, thus
326 confirming the higher efficiency of these agents against *E. coli* isolates at Kisumu County.

327 Surprisingly, out of the four isolates, 3 (75%) isolates (**12583**, **14421** & **11985**) were able to
328 produce the haemolysin, a finding that didn't conform with a previous study [46] which shows
329 100% isolates producing the enzyme. As stated before, purified haemolysin can cause fluid
330 accumulation [32], in contrast to the watery fluid produced in response to CT, the accumulated
331 fluid produced in response to haemolysin is invariably bloody with mucus [32]. Also, out of the
332 four isolates 2 (50%) (**12583** and **14421**) had the ability to produce lipase. Our findings also
333 concur with other studies, which showed that 50% isolates obtained in the study had the ability
334 to produce lipase [16]. Lipase enzymes catalyze the hydrolysis of the ester bonds of
335 triacylglycerols and may have a critical role in *P. aeruginosa* pathogenicity or nutrition
336 acquisition. The production of an excess lipase allows bacteria to penetrate fatty tissue with the
337 consequent formation of abscesses [48]. The production of these enzymes by the isolates may
338 reflect the presence of genetic organization of a discrete genetic element, which encodes three
339 genes responsible to produce proteases, lipases and phospholipase. This organization could be a
340 possible part of a pathogenic island, encoding a product capable of damaging host cells and
341 being involved in nutrient acquisition [49].

342 Some studies have suggested that Cefuroxime and Amikacin do inhibit growth at high
343 concentrations [50, 51] but from this study, it was deduced that they inhibit biofilm formation at
344 both lower and higher concentrations. The same scenario was also observed in most antibiotics

345 like Ciprofloxine, Ampicillin, ceftriaxone and Gentamicin with such ‘Goldilocks’ effect. A
346 possible explanation to the less activity observed at greater doses could be associated with the
347 aggregation effects of the antibiotics at site of entry into bacteria cells especially at high dosages
348 something that is not observed at lower dosages. It is likely that aggregation may favor biofilm
349 formation as antibiotics struggle to reach the point of action and hence bacteria will continue to
350 thrive and hence form more biofilms [52].

351 **CONCLUSION**

352 The world is in dire need of improved antimicrobial owing to escalating AMR by a wide array of
353 microbes on current antimicrobial pharmaceuticals. This calls for a continuum of research efforts
354 and innovation strategies aimed to catch up with AMR pace. This includes gene-mining
355 applications, high-throughput genetic sequencing and molecular biology approaches, as well as,
356 the recent incorporation of in silico tools and artificial intelligence (AI) in the antimicrobial
357 search. That said, the collection of clinical AMR data remains pivotal in monitoring trends in
358 antimicrobial resistance, in development of improved AMR drugs and in incorporation of
359 innovative strategies such as AI. More focus is needed on the increasing bacterial antibiotic
360 resistance especially in chronic wound management.

361 From this study, it can be concluded that antibiotic resistance patterns in Gram-positive and
362 Gram-negative bacteria are in an alarming trend that leads to the failure of treatment. The
363 resistance isolates do produce various virulence enzymatic factors such as haemolysin, lipase,
364 protease and phospholipase, that are pivotal to aiding bacterial resistance. As much as inhibitory
365 effects were recorded, these findings clearly demonstrate that the isolates proved to be resistant
366 to commonly used antibiotics and they do form biofilms. And from the higher positive growth on
367 the aspirant samples than the swab one we can conclude that the aspirant sample is the ideal
368 sample for wound culture.

369 **Acknowledgements**

370 We thank JOOTRH Laboratories-Kisumu, Kenya for providing laboratory space and other
371 resources used this study lastly, we would like to thank all staff in the microbiology section for the
372 analysis of the samples.

373 **Author contributions**

374 All authors contributed equally to this work.

375 **Conflicts of interest**

376 The authors declare that there are no conflicts of interest.

377 **References**

- 378 1. Mulani, M.S., Kamble, E.E., Kumkar, S.N., Tawre, M.S. and Pardesi, K.R., 2019.
379 Emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance:
380 a review. *Frontiers in microbiology*, 10, p.539.
- 381 2. Rice, L.B., 2008. Federal funding for the study of antimicrobial resistance in nosocomial
382 pathogens: no ESKAPE. *The Journal of infectious diseases*, 197(8), pp.1079-1081.
- 383 3. Fauci, D. Longo, E. Braunwald et al., "Patient management algorithms," in *Harrison's*
384 *Principles of Internal Medicine*, pp. 325–328, TheMcGraw-Hill Companies Inc, 17th
385 edition, 2008.
- 386 4. A. Shittu, D. Kolawole, and E. Oyedepo, "A study of wound infections in two health
387 institutions in Ile-Ife, Nigeria," *African Journal of Biomedical Research*, vol. 5, pp. 97–
388 102, 2002.
- 389 5. P. G. Bowler, B. I. Duerden, and D. G. Armstrong, "Wound microbiology and associated
390 approaches to wound management," *Clinical Microbiology Reviews*, vol. 14, no. 2, pp.
391 244–269, 2001.
- 392 6. R. Cooper, "Understanding wound infection," in *EWMA Position Document: Identifying*
393 *Criteria for Wound Infection*, MEP Ltd, London, UK, 2005.
- 394 7. C. N. Ohalete, R. K. Obi, and M. C. EmeaKorooha, "Bacteriology of different wound
395 infection and their antimicrobial susceptibility patterns in Imo state Nigeria," *World*
396 *Journal of Pharmaceutical Sciences*, vol. 13, no. 3, pp. 1155–1172, 2012.
- 397 8. Church, D., S. Elsayed, O. Reid, B. Winston and R. Lindsay. 2006. Burn wound
398 infection. *Clin. Microbiol. Rev.* 19: 403-434.
- 399 9. Gupta, N., V. Gautam, S. Saini, L. Singh, and D.R. Arora.2002. Prevalence of multi drug
400 organism in wound infection. *J. infect. Dis. Antimicrobial. Agent.* 19: 111-117.
- 401 10. Esebelahie, N.O., F.O. Esebelahie and R. Omoregie. 2013. Aerobic bacterial isolates
402 from wound infection. *Afr. J. Cln. Exper. Microbiol.* 14: 155-159.
- 403 11. Shittu, A.O., D.O. Kolawole, and E.A.R. Oyedepo. 2002. Wound infections in two health
404 institutions in Ile Ife, Nigeria: A cohort Study. *Afr. J. Biomed. Res* 5:97-102.
- 405 12. Murugan S, Mani KR, Uma DP. Prevalence of methicillin resistant staphylococcus
406 aureus among diabetes patients with foot ulcers and their antimicrobial susceptibility
407 pattern. *Journal of Clinical and Diagnostic Research.* 2008; 14(2): 979-984.
- 408 13. Jain SK, Barman R. Bacteriological profile of diabetic foot ulcer with special reference to
409 drug-resistant strains in a tertiary care center in North-East India. *Indian Journal of*
410 *Endocrinology and Metabolism.* 2017; 21(5): 688-694.
- 411 14. Alsadig MA, Elzen AA, Alshahed A, Gurfa AA, Aziza HM, Gaeidaa AM, et al.
412 Identification and determination of antibiotic resistance of pathogenic bacteria isolated
413 from septic wounds. *Journal of Advanced Laboratory Research in Biology.* 2015; 6(5):
414 97-101.

- 415 15. Mulani MS, Kamble EE, Kumkar SN, Tawre MS, Pardesi KR. Emerging strategies to
416 combat ESKAPE pathogens in the era of antimicrobial resistance: A review. *Frontiers in*
417 *Microbiology*. 2019; 10: 539-544.
- 418 16. Moellering RC. Linezolid: The first oxazolidinon antimicrobial. *Annals of Internal*
419 *Medicine*. 2003; 138(2): 135-42.
- 420 17. Ibrahim, A. A., Bhatawadekar, M. S., Peerzada, B. Y., Modak, M. M., & Lahiri, K. K.
421 (2016). Bacterial profile of diabetic foot ulcer- Study from Western India. *International*
422 *Journal of Health Sciences and Research*. (2016); 6 (5), 65-71.
- 423 18. Pai, D. R., & Madan, S. S. Techniques in chronic wound management: Review of the
424 literature and recent concepts. *Journal of Novel Physiotherapies*. (2013); 3 (2), 1-7.
- 425 19. Pokhrel P, Shrestha A, Panthi P, Manadhar S, Chaudhary DK. Bacteriological profile and
426 antibiotic susceptibility pattern of wound infection in children. *Ecronicon Microbiology*.
427 2017; 5(3): 93-100.
- 428 20. Gupta, V. An update on newer β -lactamases. *Indian Journal of Medical Research*.
429 (2007); 126, 417-427.
- 430 21. Hout, B., Oum, C., Men, P., Vanny, V., Supaprom, C., Heang, V., et al. Drug resistance
431 in bacteria isolated from patients presenting with wounds at a nonprofit surgical center in
432 Phnom Penh, Cambodia from 2011–2013. *Tropical Diseases, Travel Medicine and*
433 *Vaccines*. (2015); 1 (4), 1-11.
- 434 22. Cheesbrough M (2006). *District Laboratory Practice in Tropical Countries*. 2nd edn.
435 Cambridge. Newyork, Melbourne, Madrid, Cape Town, Singapore, Sao Paulo:
436 Cambridge University Press.
- 437 23. CLSI. 2022. Performance standards for antimicrobial susceptibility testing. thirty-second
438 Informational Supplement.33:1-199.
- 439 24. Magiorakos, A.P., Srinivasan A., Carey, R.B., Carmeli Y., Falagas, M.E., Giske C.G.,
440 Harbarth S., Hindler, J.F., G. Kahlmeter, Olsson-Liljequist B., Paterson D.L., Rice L.B.,
441 Steling J., Struelens, M.J., Vatopoulos, A., Weber, J.T. and Monner, D.L. 2012.
442 Multidrugresistant, extensively drug resistant and pandrugresistant bacteria: an
443 international expert proposal for interim standard defination for acquired resistance. *Clin.*
444 *Microbiol. Infect.* 18: 268-281.
- 445 25. European Committee for Antimicrobial Susceptibility Testing: 2000. Determination of
446 minimum inhibitory concentrations (MICs) of antibacterial agents by agar dilution.
447 *Eucast Definitive Document*. E. Def 3.1.
- 448 26. Andrews, J.M 2001. Determination of minimum inhibitory concentrations. *Journal of*
449 *Antimicrobial Chemotherapy Suppl.* 48, SL, 5-16.
- 450 27. Awuor, S.O., Omwenga, E.O., Mariita, R.M. and Daud, I.I., 2022. Cholera outbreak:
451 antibiofilm activity, profiling of antibiotic-resistant genes and virulence factors of
452 toxigenic *Vibrio cholerae* isolates reveals concerning traits. *Access Microbiology*, 4(3).
- 453 28. Benson HJ. *Microbiological Applications: Laboratory Manual in General Microbiology*.
454 8th edn. Complete version. U.S.A: McGraw-Hill; 2002.
- 455 29. Elliot EL, Kaysner CA, Jackson L, Tamplin ML. Valnificus and other *Vibrio* spp. In:
456 Merker R (eds). *Food and Drug Administration: Bacteriological Analytical Manual,*
457 *Chapter 9*, 8th ed. Gaithersburg, MD: AOAC International; 2001
- 458 30. Dogan B, Boor KJ. Genetic diversity and spoilage potentials among *Pseudomonas* spp.
459 isolated from fluid milk products and dairy processing plants. *Appl Environ Microbiol*
460 2003; 69:130–138.

- 461 31. CLSI. *Performance standards for antimicrobial sensitivity testing*. 30th ed. CLSI
462 supplement M100. Wayne, PA: Clinical Laboratory Standards Institute. 2010.
- 463 32. Halpern M, Izhaki I. Fish as hosts of *Vibrio cholerae*. *Front Microbiol* 2017; 8:282.
- 464 33. Akinjogunla, O. J., Adeko, A.A., Mboto, C.I., Chukwudebelu I.C. and Udokang I.p.
465 2009. Bacteriology of framycetin and silver sulphadiazine as topical agents for burn. A
466 pilot study. *Burns*.**35**: 672-676.
- 467 34. Giocometti, A., O. Cirioni, A.M. Schimizzi, M.S. Del, F. Prete, M.M.D Barchiesi, E.
468 Errico, G. Petrelli and J. ScaliSe. 2000. Epidemiology and microbiology for surgical
469 wound infection. *J. Clin. Microbiol.* **38**: 918- 922.
- 470 35. Iregbu, K.C., N.S. Uwaezuoke, I.P. Nwajiobi-Princewill, S.O, Eze, N. Medugu , S.
471 Shettima and Z, Modibbo. 2013. A profile of wound infecgtion in national hospital
472 Abuja. *Afr. J. Cln. Exper. Microbio.* **14**: 160-163.
- 473 36. Esebelahie, N.O., F.O. Esebelahie and R. Omoregie. 2013. Aerobic bacterial isolates
474 from wound infection. *Afr. J. Cln. Exper. Microbiol.* **14**: 155-159.
- 475 37. Thanni, L.O.A., O.A. Olunmi, and M.D. Agboola. 2003. Prevalence of bacterial
476 pathogens in infected wound in a tertiary hospital, (1995-2001): *J. Natl. Med. Assoc.*
477 **95**:1189-1195.
- 478 38. Mehta, P.A., C.K. Cunningham, L.B. Colella, G. Alferis and L.B. Weiner. 2000. Risk
479 factors for sternal wound infection and other infection in pediatric cardiac surgery
480 patients. *J. Pediatr. Infect. Dis.* **19**: 1000-1004.
- 481 39. Mohammed, A., G.O. Adeshina, and Y.K.E. Ibrahim. 2013. Retrospective incidence of
482 wound infections .and antibiotic sensitivity pattern: A study conducted at the Aminu
483 Kano Teaching Hospital, Kano, Nigeria. *International Journal of Medicine and Medical
484 Sciences* **5**: 60-66.
- 485 40. Jawetz E, Melnick JI, Adelberg EA. *Medical Microbiology*. 27th Edn. Appleton and
486 Lange U.S.A, 2016.
- 487 41. Herrington DA, Hall RH, Losonsky G, Mekalanos JJ, Taylor RK, *et al*. Toxin, toxin-
488 coregulated pili, and the toxR regulon are essential for *Vibrio cholerae* pathogenesis in
489 humans. *J Exp Med* 1988; 168:1487–1492.
- 490 42. Chen L, Wen Y. The role of bacterial biofilm in persistent infections and control
491 strategies. *Int J Oral Sci* 2011; 3:66–73.
- 492 43. Jabik NA. *Study of some Genetic Aspects of Isolated V. cholerae in Babylon*. M.Sc.
493 Thesis, University of Babylon, Iraq; 2000.
- 494 44. Poole K. Bacterial stress responses as determinants of antimicrobial resistance. *J*
495 *Antimicrob Chemother* 2012; 67:2069–2089.
- 496 45. Ammons MCB. Anti-biofilm strategies and the need for innovations in wound care.
497 *Recent Pat Antiinfect Drug Discov* 2010; 5:10–17.
- 498 46. Tan S-E, Chew SC, Tan S-Y, Givskov M, Yang L. Emerging frontiers in detection and
499 control of bacterial biofilms. *Curr Opin Biotechnol* 2014; 26:1–6.
- 500 47. Naik, G. and S.R. Deshpande. 2011. A study on surgical site infections caused by
501 *Staphylococcus aureus* with a special search for methicillin-resistant isolate. *J. Clin. and
502 Diag. Research.* **5**:502-508.
- 503 48. Abbass NBM. *Effectiveness of some physical and chemical factors on the morphological
504 changes of Vibrio cholerae isolated from environment*. Ph.D. Thesis, University of Al
505 Mustansyria, Iraq; 2006.

- 506 49. Al-Hadrawy HAN. *A Comparative study of Bacteriological and Molecular Vibrio*
507 *Cholera Isolated from the Tigris and Euphrates*. PhD Thesis, University of Kufa in
508 Arabic, Iran; 2012.
- 509 50. Ammons MCB. Anti-biofilm strategies and the need for innovations in wound care.
510 *Recent Pat Antiinfect Drug Discov* 2010; 5:10–17.
- 511 51. Xu KD, McFeters GA, Stewart PS. Biofilm resistance to antimicrobial agents.
512 *Microbiology* 2000; 146:547–549.
- 513 52. Liu, Y., Yang, Y., Zhang, C., Huang, F., Wang, F., Yuan, J., Wang, Z., Li, J., Li, J., Feng,
514 C. and Zhang, Z., 2020. Clinical and biochemical indexes from 2019-nCoV infected
515 patients linked to viral loads and lung injury. *Science China Life Sciences*, 63(3), pp.364-
516 374.
- 517

518 **Results.**

519 **Table 1:** Sociodemographic characteristics of patients involved in the study for the period of
 520 May to August 2022

Characteristic	Total (N, %)	Gram Positive (n, %)	Gram Negative (n, %)	No Growth	P Value
Age Category					
< 5 years	12 (9%)	1 (8.3%)	6 (50%)	5 (41.7%)	0.199
6-14 years	24 (17.9%)	9 (37.5%)	6 (25%)	9 (37.5%)	
15-24 years	15 (11.2%)	8 (53.3%)	2 (13.3%)	5 (33.3%)	
25-34 years	16 (11.9%)	2 (12.5%)	6 (37.5%)	8 (50%)	
35-44 years	15 (11.2%)	3 (20%)	4 (26.7%)	8 (53.3%)	
>45 years	52 (38.8%)	14(26.9%)	12 (23.1%)	26 (50%)	
Median Age (IQR)	34 (IQR 13-56)	25 (IQR 12-54)	32.5 (IQR 12-53.5%)	43 (IQR 22-59.5)	
Gender					
Female	55 (41%)	14 (25.5%)	10 (18.2%)	31 (56.4%)	0.075
Male	79 (59%)	23 (29.1%)	26 (32.9%)	30 (38%)	
Total	134	37 (27.6%)	36 (26.9%)	61 (45.5%)	

522 **Table 2:** Distribution of pathogens by sample type and gram staining technique.

Sample	Total (N, %)	<i>S. Aureus</i>	<i>Staphylococcus</i> <i>spp.</i>	<i>Klebsiella</i> <i>spp.</i>	<i>P. Aeruginosa</i>	<i>E. coli</i>	No growth
Swab	71(52.6%)	9(12.7%)	3(4.2%)	3(4.2%)	1(1.4%)	0%	55 (77.5%)
Aspirate	64(47.4%)	19(29.7%)	6(9.4%)	17(26.6%)	9(14.1%)	6(9.4%)	7 (10.9%)
Total	135(100%)	28(20.7%)	9(6.7%)	20(14.8%)	10(7.4%)	6(4.4%)	62 (45.9%)

523 **Table 3:** Antibiotic resistant patterns of isolated pathogens

Gram Positive	Cefoxitin	Oxacillin	Vancomycin	Penicillin	Cotrimoxazole	Clindamycin	Tetracycline	Gentamicin	Erythromycin
<i>S. aureus</i>	3(11.1%)	2(7.4%)	2(7.4%)	5(18.5%)	13(48.1%)	7(25.9%)	5(18.5%)	4(14.8%)	7(25.9%)
<i>Staphylococcus</i> <i>spp.</i>	2(25%)	0%	1(12.5%)	1(12.5%)	3(37.5%)	1(12.5%)	1(12.5%)	1(12.5%)	1(12.5%)
Gram Negative	Cotrimoxazole	Ciprofloxacin	Cefuroxime	Ceftriaxone	Cefepime	Imipenem	Ampicillin	Gentamicin	Amikacin
<i>Klebsiella</i> spp.	5 (27.8%)	4 (22.2%)	1 (5.6%)	3 (16.7%)	3 (16.7%)	6 (33.3%)	11(61.1%)	9 (50%)	2 (11.1%)
<i>P. aeruginosa</i>	0%	1(10%)	2 (20%)	1 (10%)	1(10%)	3 (33.3%)	2 (20%)	2 (20%)	
<i>E. coli</i>	0%	0%	0%	0%	0%	1(16.7%)	0%	0%	0%

524

525

526


527 **Table 4:** Detection of some virulence factors of *P. aeruginosa*

528

Isolates	Haemolysin	Protease	Lipase	Phospholipase
<i>12583</i>	+p	+p	+p	-n
<i>13642</i>	-n	-n	-n	-n
<i>14421</i>	+p	+p	+p	+p
<i>11985</i>	+p	+p	-n	+p

529 p = Positive and n = Negative


530 **Fig. 1:** Multidrug resistance antimicrobial class resistant to *P. aeruginosa*.



531

532

533 **Fig. 2.** Antibiofilm formation activity against isolate **12583** of *P. aeruginosa* against various
534 antibiotics: (a) Ciprofloxacin (b) Cefuroxime, (c) Ceftriaxone, (d) Ampicillin, (e) Gentamicin
535 and (f) Amikacin; PC=*P. aeruginosa* ATCC® 12934 – Positive control ($n=3$, ANOVA Dunnett's
536 multiple comparisons test; * $P=0.05$; ** $P=0.01$; *** $P=0.001$; **** $P=0.0001$).




537

538

539 **Fig. 3.** Antibiofilm formation activity against isolate 14421 of *P. aeruginosa* against various
540 antibiotics: (a) Ciprofloxacin (b) Cefuroxime, (c) Ceftriaxone, (d) Ampicillin, (e) Gentamicin
541 and (f) Amikacin; PC=*P. aeruginosa* ATCC® 12934 – Positive control ($n=3$, ANOVA Dunnett's
542 multiple comparisons test; * $P=0.05$; ** $P=0.01$; *** $P=0.001$; **** $P=0.0001$).

543



544


545

546

547 Fig. 4. Antibiofilm formation activity against isolate **11985** of *P. aeruginosa* against various
548 antibiotics: (A) Ciprofloxacin (B) Cefuroxime, (C) Ceftriaxone, (D) Ampicillin, (E) Gentamicin
549 and (F) Amikacin; PC=*P. aeruginosa* ATCC® 12934 – Positive control ($n=3$, ANOVA Dunnett's
550 multiple comparisons test; * $P=0.05$; ** $P=0.01$; *** $P=0.001$; **** $P=0.0001$).

551

552



553

554